You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 131 No. 12, December 1995 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Studies
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (49)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

The Antipruritic Effect of 5% Doxepin Cream in Patients With Eczematous Dermatitis

Lynn A. Drake, MD; Larry E. Millikan, MD; Doxepin Study Group

Arch Dermatol. 1995;131(12):1403-1408.


Abstract



Background and Design
Eczematous dermatitis is commonly characterized by intense pruritus. Current treatment modalities for this condition, regardless of its cause, are primarily directed at blunting the cutaneous inflammatory response and thereby providing relief of pruritus. To expand on our previous findings in atopic dermatitis, the present multicenter double-blind trial was conducted to evaluate the safety and antipruritic efficacy of 5% doxepin hydrochloride cream in patients with lichen simplex chronicus (n=136), nummular eczema (n=87), or contact dermatitis (n=86). A total of 309 patients with moderate to severe pruritus were randomly assigned to apply either doxepin cream (n=154) or vehicle cream (n=155) to eczematous areas four times per day for a period of 7 days. Efficacy was assessed using a pruritus severity rating scale, a Physician's Global Evaluation for pruritus relief, and a Visual Analogue Scale for pruritus relief.

Results
Twenty-four hours after initiation of treatment, and continuing throughout the remainder of the study, patients treated with doxepin cream experienced significantly greater pruritus relief than did vehicletreated patients as determined by all efficacy parameters (P<.002). Sixty percent of doxepin-treated patients experienced pruritus relief within 24 hours. The response rate increased to 84% by conclusion of the study. As judged by significant changes (P≤.05) occurring in at least one assessment of efficacy, doxepin cream provided pruritus relief in all forms of eczematous dermatitis that were examined. The study medication was well tolerated. The two most common adverse effects, stinging at the site of application and drowsiness, were usually transient and mild to moderate in severity.

Conclusion
Topical application of doxepin provides significant antipruritic activity with a favorable safety profile, suggesting a role for doxepin cream in the symptomatic treatment of pruritus associated with eczematous dermatitis.

(Arch Dermatol. 1995;131:1403-1408)



Author Affiliations



From the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston (Dr Drake), and the Department of Dermatology, Tulane University, New Orleans, La (Dr Mallikan). For a list of the members of the Doxepin Study Group, see box on page 1407.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Efficacy of Gabapentin in the Management of Pruritus of Unknown Origin
Yesudian and Wilson
Arch Dermatol 2005;141:1507-1509.
FULL TEXT  

Topical and Peripherally Acting Analgesics
Sawynok
Pharmacol. Rev. 2003;55:1-20.
ABSTRACT | FULL TEXT  

Doxepin cream for eczema?
DTB 2000;38:31-32.
ABSTRACT | FULL TEXT  

Eczematous Dermatitis?
Sherertz and Soni
Arch Dermatol 1996;132:1130-1130.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.